Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company’s medicines platform, PRISM combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a GalNAc-conjugated RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; WVE-007, a GalNAc-conjugated small interfering RNA designed to silence INHBE mRNA targeting obesity; WVE-008, a GalNAc-conjugated RNA editing oligonucleotide for the treatment of liver disease; WVE-N531, an exon splicing oligonucleotide for the treatment of Duchenne muscular dystrophy; and WVE-003, an allele-selective oligonucleotide for the treatment of Huntington’s disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was founded in 2012 and is based in Singapore.
Financial Health | Discover Wave's financial landscape, balancing a healthy current ratio against rapid cash burn, as it navigates critical development stages in the biotech secto |
Market Positioning | Learn how Wave aims to differentiate itself in competitive markets through less frequent dosing and novel mechanisms, with analyst price targets ranging from $9 to $36 |
Clinical Milestones | Delve into Wave's pipeline progress, with key data readouts expected in 2025 for AATD and obesity programs, potentially validating its RNA editing platform |
RNA Editing Pionee | Explore Wave Life Sciences' innovative approach to genetic medicine, leveraging RNA editing technology for potential breakthroughs in AATD, obesity, and other disorders |
Metrics to compare | WVE | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipWVEPeersSector | |
|---|---|---|---|---|
P/E Ratio | −6.9x | −7.2x | −0.5x | |
PEG Ratio | 0.09 | −0.14 | 0.00 | |
Price / Book | 2.7x | 2.0x | 2.6x | |
Price / LTM Sales | 33.0x | 10.8x | 3.2x | |
Upside (Analyst Target) | 183.6% | 36.6% | 47.6% | |
Fair Value Upside | Unlock | −5.7% | 6.1% | Unlock |